Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1002/wrna.43

http://scihub22266oqcxt.onion/10.1002/wrna.43
suck pdf from google scholar
21957005!7169851!21957005
unlimited free pdf from europmc21957005    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid21957005      Wiley+Interdiscip+Rev+RNA 2011 ; 2 (2): 184-92
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • The RNA capping machinery as an anti-infective target #MMPMID21957005
  • Issur M; Picard-Jean F; Bisaillon M
  • Wiley Interdiscip Rev RNA 2011[Mar]; 2 (2): 184-92 PMID21957005show ga
  • A number of different human pathogens code for their own enzymes involved in the synthesis of the RNA cap structure. Although the RNA cap structures originating from human and microbial enzymes are often identical, the subunit composition, structure and catalytic mechanisms of the microbial-encoded enzymes involved in the synthesis of the RNA cap structure are often significantly different from those of host cells. As a consequence, these pathogenic cap-forming enzymes are potential targets for antimicrobial drugs. During the past few years, experimental studies have started to demonstrate that inhibition of the RNA capping activity is a reasonable approach for the development of antimicrobial agents. The combination of structural, biochemical, and molecular modeling studies are starting to reveal novel molecules that can serve as starting blocks for the design of more potent and specific antimicrobial agents. Here, we examine various strategies that have been developed to inhibit microbial enzymes involved in the synthesis of the RNA cap structure, emphasizing the challenges remaining to design potent and selective drugs.
  • |*Drug Design[MESH]
  • |Animals[MESH]
  • |Anti-Infective Agents/*chemical synthesis/chemistry[MESH]
  • |Humans[MESH]
  • |Models, Biological[MESH]
  • |Models, Molecular[MESH]
  • |Molecular Targeted Therapy/*methods[MESH]
  • |Nucleotidyltransferases/antagonists & inhibitors/metabolism[MESH]
  • |Phosphates/chemical synthesis/chemistry[MESH]
  • |RNA Cap Analogs/chemical synthesis/chemistry[MESH]
  • |RNA Caps/*antagonists & inhibitors/*metabolism[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box